Google
NAUT Stock Price & Analysis — Nautilus Biotechnology Inc (Healthcare >> Biotechnology)
NAUT FAQ
What is NAUT's ROE?
Nautilus Biotechnology Inc reports a Return on Equity (ROE) of -43.11%.
What is NAUT's dividend yield?
Nautilus Biotechnology Inc offers a dividend yield of 0.00%.
What is NAUT's Quality Score?
Our AI rates NAUT's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NAUT?
Our AI Timing Score for NAUT is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NAUT belong to?
Nautilus Biotechnology Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
NAUT AI Analysis Summary
Our AI summary for NAUT: Nautilus Biotechnology Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -43.11%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.99
Price
-0.02
(-2.45%)
Day Change
|
|
|---|
NAUT, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.99 |
| PBV / Sector |
0.98 / 44,022.72
GREAT
|
| Earning Per Share | -0.43 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
1.44 M
GREAT
|
| Average 1W Daily Value |
1.41 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-05 08:00:34 |
| Symbol | NAUT |
| Name | NAUTILUS BIOTECHNOLOGY INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 127.08 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 128.35 / 9,586.08 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2701 Eastlake Avenue East, Seattle, WA, United States, 98102
Phone: 206 333 2001
Website: https://www.nautilus.bio
Employees: 127
Sector: Healthcare >> Biotechnology
Description: Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap